Reuters logo
BRIEF-Ophthotech says Fovista phase 3 trial did not meet primary endpoint
December 12, 2016 / 6:08 AM / a year ago

BRIEF-Ophthotech says Fovista phase 3 trial did not meet primary endpoint

Dec 12 (Reuters) - Ophthotech Corp :

* pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials

* addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point

* based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen

* Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below